Named to the Washington DC Rising Stars list in the area of Food and Drugs (from 2018 to 2020), attorney Delia Deschaine focuses her practice on advising pharmaceutical and biotechnology clients on a broad range of FDA and DEA regulatory matters. Her services include:

  • Providing advice on pharmaceutical and biotechnology development and approval
  • Advising on pharmacovigilance, current Good Manufacturing Practices (“cGMPs”) compliance, Risk Evaluation and Mitigation Strategies (or “REMS”), registration and listing, field alert reporting, import and export matters, recalls, labeling, advertising and promotion, and Drug Supply Chain Security Act compliance
  • Conducting internal investigations, and defending clients in government investigations and litigation
  • Representing manufacturers and their suppliers in responding to Form FDA 483s, Warning Letters, and Import Alerts
  • Drafting and negotiating commercial agreements and conducting diligence in corporate transactions

Read more

Delia has a deep understanding of FDA requirements related to cGMP and FDA Quality System Regulations (“QSR”). She routinely counsels clients on their obligations related to cGMP and QSR, including quality systems, data integrity, supply chain management, aseptic processing, validation, and sterilization. 

In addition, Delia focuses her practice on the federal and state regulation of controlled substances. She defends clients, including pharmaceutical and biotechnology companies, distributors, pharmacies, hospitals, physician groups, academic medical centers, and other researchers, in government investigations and litigation, and advises them on:

  • Controlled substances scheduling matters
  • Compliance with U.S. Drug Enforcement Administration (“DEA”) and state law regulatory requirements
  • Conducting internal investigations

Delia also counsels clients on cannabis law issues and matters involving psychedelic substances. She was selected to the Washington DC Rising Stars list in the area of Cannabis Law in 2020 and named one of the top 200 psychedelic lawyers in the United States in 2024. Delia has advised pharmaceutical, researcher, conventional food, dietary supplement, and cosmetic companies on FDA, DEA, U.S. Department of Agriculture, and states’ regulation of cannabis (including hemp), cannabis-derived products, synthetic cannabinoids, and psychedelic, psychotropic, and other Schedule I controlled substances.

Prior to joining the firm, Delia served for six years as an attorney for an international law firm in the areas of pharmaceutical and biotechnology law, and two years at a boutique FDA law firm, both in Washington, DC. Before then, she was an Attorney Advisor for the DEA through the Attorney General’s Honors Program, where she received a Performance Award in 2011. She was also a legal intern for Magistrate Judge Susan K. Gauvey of the U.S. District Court for the District of Maryland.

Read less

Focus Areas


  • Represented a pharmaceutical company in an appeal of a Complete Response Letter, leading to a favorable FDA Advisory Committee Meeting and approval of the drug.
  • Drafted citizen petitions for pharmaceutical and biotechnology clients on novel issues of drug approval.
  • Assisted a biotechnology client nearing launch on construction of an FDA compliance program, including contract manufacturing arrangements, pharmacovigilance, drug registration and listing, NDC/labeler code requirements, and state licensing matters.
  • Drafted and negotiated contract manufacturing agreements, and related quality agreements, on behalf of gene therapy companies and other pharmaceutical and biotechnology clients.
  • Revised supply and distribution agreements for a pharmaceutical manufacturer of controlled substances.
  • Defended a client in a high-profile government investigation and litigation regarding the client’s compliance with DEA’s suspicious order monitoring requirements, leading to a court enjoining DEA’s immediate suspension order and a favorable outcome of an administrative proceeding.
  • Defended a pharmaceutical manufacturer in a government investigation, leading to a nulle proseque of allegations of criminal federal Food, Drug, and Cosmetic Act violations.
  • Represented several manufacturers in responding to Form FDA 483s and Warning Letters, in every case resulting in no (or no further) enforcement action from the FDA.
  • Represented a client in obtaining a letter from the DEA finding that the client’s development of a cannabinoid drug product was not Schedule I.
  • Advised a pharmaceutical manufacturer of a cannabinoid drug product on navigating the DEA scheduling process while the cannabinoid-drug product was undergoing FDA review.
  • Advised a prominent Canadian cannabis company on a broad range of U.S. cannabis law matters, including the federal and state regulation of cannabis topicals, edibles, and smokeables, and regulation of cannabidiol.
  • Advised a biosynthetic manufacturer of cannabis products on U.S. cannabis law matters.
  • Represented a client in an application for a DEA cannabis cultivation registration for research.
  • Represented a client in an application for a Maryland cannabis cultivation license for purposes of supplying legitimate research in the United States.


  • The Best Lawyers in America, Cannabis Law (2023-2024)
  • “Global Top 200 Psychedelic Lawyers” Directory – 3rd Edition, Top 200 Psychedelic Lawyers in the United States (2024)



  • University of Maryland Francis King Carey School of Law (J.D., cum laude, 2010)
    • Health Law Certificate
    • Health Law Moot Court
  • Manhattanville College (B.A., 2004)
    • Board of Trustees Scholar

Bar Admissions

Professional & Community Involvement

  • Food and Drug Law Institute, Cannabis Regulatory Products Committee (2020 to 2021)
  • Food and Drug Law Institute, Medical Products Committee (2022)
  • Epping Forest, Inc., Board of Directors, Legal Chair





Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.